40 results about "Chemosensitizer" patented technology

Methods of detecting novel therapeutically active compositions based on their ability to modulate the glycolipid metabolism and overcome multidrug resistance are described. These methods are particularly useful in screening for novel chemotherapeutic agents for the treatment of cancer, as well as chemosensitizers that are capable of enhancing the cytotoxicity of such chemotherapeutic agents. A combination of one or more of these compositions can be used in the treatment of a various cancers.

The invention discloses a chemotherapy-sensitizing polypeptide aggregate and its preparation method and application. The polypeptide combination is composed of two polypeptide fragments with different functions, one of which has a target recognition function, and the other contains an assembly unit and has an assembly function. Driving function, the two polypeptides can self-assemble through efficient click reaction to form polypeptide aggregates with chemosensitizing effect. The method disclosed in the present invention can aggregate the polypeptide at the target site through specific design, improve the retention capacity of the polypeptide through the aggregation behavior at the target site, and at the same time, the aggregation of the polypeptide can disturb the cell membrane to promote the uptake of chemotherapy drugs by cancer cells. Through the design of the polypeptide aggregate and the selection of indications, the present invention provides a new idea for the transformation and development of the polypeptide aggregate, and also provides a new treatment method for the chemotherapy of cancer cells, especially drug-resistant cancer cells.

The present invention relates to novel TMPK inhibitor and their methods of use. In particular, it relates to novel TMPK inhibitor of Formula (I) and therapeutics that decrease the cellular dTTP level to suppress the growth and inhibit DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.

The invention belongs to the field of medicine, and relates to the application of 2α-hydroxyprotopanaxadiol in the preparation of antitumor drugs, especially the application of 2α-hydroxyprotopanaxadiol in the preparation of antitumor drug resistance reversal agents. 2α-Hydroxyprotopanaxadiol is a natural product that can reverse the multidrug resistance of tumor cells and can be used as a reversal agent for tumor multidrug resistance; 2α-Hydroxyprotopanaxadiol can also increase the resistance of tumor multidrug-resistant cells The role of tumor drug sensitivity can be used as a chemosensitizer. The invention also provides a medicine method for inhibiting the proliferation of tumor multidrug-resistant cells by using the pharmaceutical composition combined with antineoplastic drugs and 2α-hydroxy protopanaxadiol. The small molecule compound 2α-hydroxy protopanaxadiol in the present invention is developed as a new anti-tumor drug or its auxiliary components, and has obvious tumor-suppressing effect and is environmentally friendly, which will provide a new way and means for treating and curing tumors .

The invention discloses a kit for postoperative and prognosis evaluation of liver cancer, and relates to the field of biological medicine. The kit comprises an agent for quantitatively detecting an expression level of micro RNA (Ribonucleic Acid) molecules miR-653 in to-be-detected liver tissues; a nucleotide sequence of the miR-653 is as shown in Seq ID No.1. Active ingredients of a liver cancer chemosensitizer comprise the mutually prepared micro RNA molecules miR-653 and a precursor of the micro RNA molecules miR-653, or an overexpression vector capable of effectively expressing the micro RNA molecules miR-653 and / or the precursor of the miR-653; the precursor of the micro RNA molecules miR-653 is encoded by a DNA (Deoxyribose Nucleic Acid) sequence as shown in Seq ID No.2. Experimental data verify the effectiveness of the kit disclosed by the invention in the aspect of postoperative and prognosis evaluation of liver cancer and verifies that the sensitizer based on the miR-653 can effectively reinforce the sensitivity of liver cancer cells for a chemotherapy drug sorafenib.

The invention discloses the preparation and application of a reduction-sensitive brain tumor targeting liposome co-modified by glucose and triphenylphosphonium, which is used to realize the efficient delivery of brain tumor targeting drugs. The new liposomes are co-modified by glucose and triphenylphosphonium, which can respectively recognize the glucose transporter GLUT1, which is highly expressed on the surface of the blood-brain barrier and brain tumor cells, and electrostatically interact with the mitochondria in the tumor cells, from cells and organelles Two levels, realize multiple targeting functions on the blood-brain barrier, tumor tissue and mitochondria, and play a stronger role in the targeted therapy of brain tumors. The new liposome can be used for combined loading of chemotherapeutic drugs and chemosensitizers acting on mitochondria for synergistic treatment of brain tumors. It has more precise targeting of brain tumors, can improve the effect of chemotherapy and reduce side effects. It has broad application prospects.